Ask AI
Advancing Heart Failure Care With MRAs

CE / CME

Advancing Heart Failure Care With Steroidal and Nonsteroidal Mineralocorticoid Receptor Agonists

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: June 17, 2025

Expiration: June 16, 2026

Activity

Progress
1 2
Course Completed

References

  1. Logeart D. Heart failure with preserved ejection fraction: New challenges and new hopes. Presse Med. 2024;53:104185.
  2. Martin SS, Aday AW, Allen NB, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 Heart disease and stroke statistics: A report of US and global data from the American Heart Association. Circulation. 2025;151:e41-e660.
  3. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-380.
  4. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: A review. JAMA. 2023;329:827-838.
  5. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-1098.
  6. Desai N, Olewinska E, Famulska A, et al. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Fail Rev. 2024;29:631-662.
  7. Laddu D, Cherupally M, Kang R, et al. Abstract P1072: Underutilization of novel guideline-directed medical therapy in patients with heart failure. Circulation. 2025;151(Suppl_1):P1072.
  8. Lopatin Y. Heart failure with mid-range ejection fraction and how to treat It. Card Fail Rev. 2018;4:9-13.
  9. Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. Eur Cardiol. 2022;17:e17.
  10. Lv R, Xu L, Che L, et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol (Lausanne). 2023;14:1125693.
  11. Chiuariu T, Șalaru D, Ureche C, et al. Cardiac and renal fibrosis, the silent killer in the cardiovascular continuum: An up-to-date. J Cardiovasc Dev Dis. 2024;11:62.
  12. Vizzardi E, Regazzoni V, Caretta G, et al. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. Int J Cardiol Heart Vessel. 2014;3:6-14.
  13. Savarese G, Lindberg F, Filippatos G, et al. Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists. Diabetologia. 2024;67:246-262.
  14. Chang J, Ambrosy AP, Vardeny O, et al. Mineralocorticoid antagonism in heart failure: established and emerging therapeutic role. J Am Coll Cardiol HF. 2024;12:1979-1993.
  15. Upadhyay A, Haider L. Mineralocorticoid receptor antagonists in diabetic kidney disease: Clinical evidence and potential adverse events. Clin Diabetes. 2024;43:43-52.
  16. Barrera-Chimal J, Kolkhof P, Lima-Posada I, et al. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs. 2021;30:1141-1157.
  17. Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: Analysis of the TOPCAT Trial. J Card Fail. 2018;24:313-320.
  18. Shah M, Awad AS, Abdel-Rahman EM. Nonsteroidal mineralocorticoid receptor antagonist (Finerenone) in cardiorenal disease. J Clin Med. 2023;12:6285.
  19. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92.
  20. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
  21. Tromp J, van der Meer P. Hyperkalaemia: aetiology, epidemiology, and clinical significance. Eur Heart J Suppl. 2019;21(Suppl A):A6-A11.
  22. Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220-3234.
  23. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
  24. Stienen S, Ferreira JP, Vincent J, et al. Estimated long-term survival with eplerenone. J Am Coll Cardiol. 2019;73:2357-2359.
  25. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1-e167.
  26. Solomon SD, McMurray JJV, Vaduganathan M, et al; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475-1485.
  27. Philipose C, Tamakuwala R. SGLT2 inhibitors are underutilized for inpatient heart failure treatment. pharmacytimes.com/view/sglt2-inhibitors-are-underutilized-for-inpatient-heart-failure-treatment. Accessed June 9, 2025.
  28. Fudim M, Grodin JL, Mentz RJ. Hyperkalemia in heart failure: Probably not O"K". J Am Heart Assoc. 2018;7:e009429.
  29. Yugar-Toledo JC, Modolo R, de Faria AP, et al. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc Health Risk Manag. 2017;13:403-411.
  30. Chun KH, Kang SM. Blood pressure and heart failure: focused on treatment. Clin Hypertens. 2024;30:15.
  31. Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404:1119-1131.
  32. Khullar D, Gupta AK, Singh K. Finerenone: Will it be a game-changer? Card Fail Rev. 2024;10:e19.
  33. Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19-35.
  34. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-2229.